For investors & LPs
Invest where commercialization creates the value.
RCP Venture Capital backs therapeutics, medical device and diagnostics companies as they move from clinical data to commercial readiness, with operators alongside the capital.
01 · Two ways to invest
Flexible investment options to fit your investor mandate.
Commit to a curated portfolio through the fund, or invest directly in a single asset through an SPV.
The fund
A fund built on operational expertise
The fund invests across a diversified portfolio of therapeutics, device and diagnostics companies. Each one is selected and supported in collaboration with Rapid Commercialization Partners, whose commercialization work informs both diligence and the value-building plan after the investment.
- A diversified portfolio across modalities and stages
- Companies screened for commercial as well as clinical risk
- Hands-on operational support from the partners after the investment
Single-asset SPVs
Concentrated conviction in one asset
For investors with a focus area or personal conviction in a particular therapeutic area, an SPV lets you invest directly in a single target asset, alongside the same commercialization diligence and operating support the fund receives.
- Direct exposure to one asset you choose
- The same diligence and operational support as the fund
- Terms shared privately for each opportunity
Specific opportunities and terms are shared privately with qualified investors on request.
02 · The operator edge
Commercial readiness, not science alone, determines outcomes.
RCP Venture Capital exists because we were already doing the hardest part of venture — identifying and mitigating commercialization risk.
Most venture funds
Typical financial investor: Capital first, commercial questions later.
- Writes larger checks, often outside the reach of early clinical-stage companies
- Diligence centered on the science and the financing round
- Commercial questions addressed later, closer to launch
- Involvement largely limited to the board seat
RCP Venture Capital
Capital with commercial partnership.
- Incremental, milestone-driven capital sized to near-term clinical or commercial goals
- Commercialization diligence: reimbursement pathway, pricing assumptions, and access risk
- Early alignment of reimbursement, regulatory strategy, positioning, and capital pacing
- A committed partnership beyond the initial deployment of capital
RCP VC collaborates with Rapid Commercialization Partners (rcpbio.com) for operational guidance and expertise. Rapid Commercialization Partners and RCP Venture Capital are separate organizations, and RCP VC investment decisions are made independently.
03 · In their words
What founders and partners say.
It really is a very unique opportunity to become more of a value creation investor than just the pure financial play.
Great science doesn’t commercialize itself. We invest where we can roll up our sleeves alongside founders, turning clinical data into a product that physicians adopt, payers cover and patients can reach.
The SPV model lets investors put their conviction behind the specific companies they believe in. And because RCP VC takes an equity stake and brings operators to the table, our incentives line up with theirs. Operating discipline early on is what drives value at the next inflection point.
04 · Investor materials
Request investor materials.
Tell us a little about yourself and the partners will follow up one on one.
Rapid Commercialization Partners (rcpbio.com) and RCP Venture Capital are separate organizations; RCP VC investment decisions are made independently. This website is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security. Any offering will be made only to qualified investors through definitive offering documents.